Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 11/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076525 | 0.92 | F2R (0.53) | F2RCNR1TMEM97AKR1C3POLB | |
| SCHEMBL1055582 | 0.90 | F2R (0.54) | F2RCNR1TMEM97AKR1C3POLB | |
| SCHEMBL1053094 | 0.90 | F2R (0.53) | F2RCNR1TMEM97AKR1C3POLB | |
| SCHEMBL1056036 | 0.88 | F2R (0.51) | F2RCNR1TMEM97AKR1C3POLB | |
| SCHEMBL1082434 | 0.85 | F2R (0.56) | F2RCNR1TMEM97AKR1C3POLB | |
| SCHEMBL1052036 | 0.85 | F2R (0.56) | F2RCNR1TMEM97AKR1C3POLB | |
| SCHEMBL640623 | 0.85 | F2R (0.59) | F2RCNR1TMEM97AKR1C3POLB | |
| SCHEMBL640793 | 0.85 | F2R (0.54) | F2RCNR1TMEM97AKR1C3POLB | |
| SCHEMBL640304 | 0.84 | F2R (0.55) | F2RCNR1TMEM97AKR1C3POLB | |
| SCHEMBL642168 | 0.84 | F2R (0.60) | F2RCNR1TMEM97AKR1C3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | VHL, PIR, PIGO | F2R 1339/4885CNR1 460/4885TMEM97 903/4885 |
| US-20120220563-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1339/4885CNR1 460/4885TMEM97 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.